We found SOX9 to be involved in a Gal-1/β-catenin-mediated enhancement of a number of in vitro CIC features including EMT-related gene expression (Figure 5); moreover, analyses of multiple human CRC transcriptome databases as well as tissue microarray immunohistological staining demonstrated a significant correlation of high SOX9 expression to tumor presence, which is highly suggestive of its utility as a CRC biomarker. Here, SOX9 is linked to colorectal carcinoma.